Anda di halaman 1dari 9

3/28/13 Molecular mechanism of alcoholic fatty liver

Indian J Pharmacol. 2012 May-Jun; 44(3): 299–303. PMCID: PMC3371448


doi: 10.4103/0253-7613.96297

Molecular mechanism of alcoholic fatty liver


Karuna Rasineni1,3 and Carol A. Casey 1,2,3
1
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
2
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA
3
Department of Biochemistry and Molecular Biology, The Liver Study Unit, VA Nebraska-Western Iow a Health Care System, Omaha, NE, USA
Correspondence to: Dr. Karuna Rasineni, E-mail: karuna.rasineni@unmc.edu

Received December 1, 2011; Revised March 1, 2012; Accepted March 1, 2012.

Copyright : © Indian Journal of Pharmacology

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, w hich
permits unrestricted use, distribution, and reproduction in any medium, provided the original w ork is properly cited.

Abstract
Ethanol abuse and chronic ethanol consumption remains a major public health problem and is
responsible for a high rate of morbidity. Alcohol-induced fatty liver generally begins as hepatic steatosis,
and if the cause persists, this invariably progresses to steatohepatitis and cirrhosis. The original
biochemical explanation for an alcoholic fatty liver centered on the ability of ethanol metabolism to
shift the redox state of the liver and inhibit fatty acid oxidation. Subsequent studies found repression of
fatty acid oxidation and that the induction of lipogenesis can occur in alcoholic conditions. Ethanol
activates sterol regulatory element binding protein 1, inducing a battery of lipogenic enzymes. These
effects may be due in part to inhibition of AMP-dependent protein kinase, reduction in plasma
adiponectin or increased levels of TNF-α the liver. They in turn activate lipogenic pathways and inhibit
fatty acid oxidation. Besides the fatty acid synthesis and oxidation, ethanol also alters lipid droplet (LD,
the storage form of triglycerides, TG) metabolism in hepatocytes and very low-density lipoprotein
(VLDL) secretion from liver. Because steatosis is now regarded as a significant risk factor for advanced
liver pathology, an understanding of the molecular mechanisms in its etiology provides new therapeutic
targets to reverse the alcoholic fatty liver.

KEY WORDS: Adiponectin, alcohol, adenosine monophosphate-activated protein kinase, lipid


droplets, steatosis/fatty liver

Introduction
Alcohol abuse and alcohol-induced liver disease (ALD) are a major public health problem both in the US
and worldwide. ALD is probably the main cause of death among people with severe alcohol abuse and is
responsible for about 3.8% of global mortality.[1] An early manifestation of alcohol liver disease (ALD)
is the presence of fatty liver (hepatic steatosis) that, with continued insult, can progress to alcoholic liver
disease (ALD).

The spectrum of disease ranges from fatty liver (steatosis) to alcoholic steatohepatitis (ASH), hepatic
fibrosis and cirrhosis.[2,3] Steatosis is an earliest stage of alcoholic liver disease and the most common
alcohol-induced liver disorder. Steatosis is characterized, in part, by the excessive buildup of fat inside
liver cells. This condition can be reversed, however, when the alcohol intake stops.[4] ASH is defined by
the presence of fatty liver, an inflammatory infiltrate (which mainly consists of polymorphonuclear

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 1/9
3/28/13 Molecular mechanism of alcoholic fatty liver

leukocytes) and hepatocellular damage.[5,6] Patients with ASH can develop progressive fibrosis. In
livers affected by ALD, the fibrotic tissue is typically located in pericentral and perisinusoidal areas,
collagen deposits are evident and bridging fibrosis develops, which precedes the development of
regeneration nodules and liver cirrhosis.[7] Cirrhosis involves replacement of the normal hepatic
parenchyma with extensive thick bands of fibrous tissue and regenerative nodules, which results in the
clinical manifestations of portal hypertension and liver failure.[8,9] The prevalence of alcoholic liver
disease is influenced by many factors, including genetic factors (e.g., predilection to alcohol abuse, sex)
and environmental factors (e.g., availability of alcohol, social acceptability of alcohol use, concomitant
hepatotoxic insults), which make this disease, difficult to define.[10] In general, however, the risk of
liver disease increases with the quantity and duration of an alcohol intake. Although necessary,
excessive alcohol use is not sufficient to promote alcoholic liver disease. Only 1 in 5 heavy drinkers
develops alcoholic hepatitis, and 1 in 4 develops cirrhosis.[11–13] The pathogenesis of ALD is
multifactorial and includes several overlapping events. The “two-hit” hypothesis postulates that the
steatotic liver is the first hit, and this steatotic liver is susceptible to secondary insults including a
vulnerability to reactive oxygen species (ROS), gut-derived endotoxins, and adipocytokines such as,
tumor necrosis factor (TNF-α) and other cytokines. All of these hits are widely believed to be major
contributors to alcohol-induced liver injury and may compound an initial steatosis. An evolving concept
that is gaining acceptance is that certain accumulated fatty acids are toxic to the liver. Thus, ethanol-
elicited hepatic lipid accumulation, as well as that caused by dietary sources, has prompted renewed
interest as a cornerstone of liver toxicity as it may not only initiate but enhance the progression of
alcoholic liver disease.[14] This review will discuss the factors that contribute to ethanol-induced
steatosis.
General Mechanism for Alcohol-induced Fatty Acid Synthesis The liver and, to a lesser extent, the
gastrointestinal tract, are the main sites of alcohol metabolism. Within the liver, there are 2 main
pathways of alcohol metabolism, alcohol dehydrogenase and cytochrome P-450 2E1 (CY P2E1). Alcohol
dehydrogenase (ADH) is a hepatocyte cytosolic enzyme that converts alcohol to acetaldehyde.
Acetaldehyde subsequently is metabolized to acetate via the mitochondrial enzyme acetaldehyde
dehydrogenase (ALDH). Both steps are coupled to the reduction of NAD to NADH.[15–17] An increased
NADH/NAD ratio has profound effects on the metabolism of carbohydrates and lipids. Gluconeogenesis
is impaired and substrate flow through the citric acid cycle is diminished with acetyl-coA diverted
towards ketogenesis and fatty acid synthesis. Together with the inhibition of mitochondrial fatty acid β-
oxidation, this latter effect of the altered redox state contributes to the pathogenesis of fatty liver
(steatosis).[16,18] This metabolic explanation for fatty liver has been a prevailing concept for many
years, but it was not sufficient to explain the rapid formation of fatty liver after an acute ethanol
administration. In addition, the degree of change in liver redox potential that occurs in vivo after
chronic ethanol administration to rodents is significant but rather modest. Thus, the metabolic
explanation for alcohol-induced fatty liver became insufficient to account for all changes that occurred
in hepatic lipids after ethanol consumption. Later discoveries in cell signaling and characterization of
specific transcription factors prompted investigations of causes that are operative in the pathophysiology
of ethanol-induced steatosis.

Updated Mechanisms in Ethanol-induced Hepatic Steatosis The total amount of fat in the liver depends on
fatty acid synthesis and its oxidation. As shown in Figure 1 the pathogenesis of alcoholic fatty liver is
based upon the combination of an increased glycerolipid synthesis and decreased fatty acid oxidation in
mitochondria. In addition to synthesis and oxidation, fatty acid export processes also influence the fat
levels.

Accelerated Synthesis The enzymes involved in fatty acid synthesis are predominantly controlled by
sterol regulatory element binding protein 1 (SREBP-1).[19] Sterol regulatory element-binding proteins
(SREBPs) are a family of transcription factors that regulate the enzymes responsible for the synthesis of

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 2/9
3/28/13 Molecular mechanism of alcoholic fatty liver

cholesterol, fatty acids, and triglycerides in liver and other tissues. SREBPs are synthesized as precursors
(~125 kDa) bound to the endoplasmic reticulum and nuclear envelope. Upon an activation, SREBPs are
released from the membrane into the nucleus as a mature protein (~68 kDa) by a sequential 2-step
cleavage process.[20] Ethanol exposure has been shown to significantly increase the SREBP-regulated
transcription via elevated levels of the mature SREBP-1 protein. Thus, ethanol increases the fatty acid
synthesis through SREBP-1. The effect of ethanol on SREBP-1 appears to be mediated through its
metabolism to acetaldehyde. Results from published work suggest that acetaldehyde can increase the
synthesis of the mature SREBP-1 protein, which enhances hepatic lipogenesis and leads to the
development of fatty liver [Figure 1].[21]

Impaired Fatty Acid Oxidation Oxidation of fatty acids occurs in 3 subcellular organelles, with β-oxidation
confined to mitochondria and peroxisomes and cytochrome P450 4A (CY P4A)-catalyzed ω-oxidation
occurring in the endoplasmic reticulum. Some of the key enzymes of these 3 fatty acid oxidation
systems in liver are regulated by peroxisome proliferator-activated receptor-alpha (PPAR-α),
adiponectin and adenosine monophosphate-activated protein kinase (AMPK).

Beta-oxidation is the major degradative pathway for fatty acid esters in humans, and this is regulated
by carnitine palmitoyltransferase-1 (CPT-1), the carnitine concentration, and malonyl-CoA, which
inhibits CPT-1.[22] With the concomitant up-regulation of fatty acid biosynthesis by ethanol, the
intracellular accumulation of intermediary products of fatty acid synthesis, such as malonyl-CoA, can
negatively affect fatty acid transport into mitochondria and its oxidation by inhibiting CPT-1. Fatty
acids, fatty acyl-CoAs, and several structurally different synthetic compounds, known as peroxisome
proliferators, can activate PPAR-α, and thus regulate CPT-1 levels in the liver.[22]
PPAR-α in hepatic steatosis Peroxisome proliferator-activated receptor-alpha (PPAR-α) is a member of
the nuclear hormone receptor super family and functions as a lipid sensor in the liver. PPAR-α
recognizes and responds to the influx of fatty acids by stimulating the transcription of PPAR-α-
regulated genes, which are involved in oxidation, transport and export of free fatty acids. These include
membrane transporters such as CPT-1, apolipoprotein genes, and several components of the
mitochondrial and peroxisomal fatty acid β-oxidation pathways.[23,24] The PPAR-α regulated enzymes
involved in fatty acid oxidation include acyl-CoA oxidase (AOX), 3-hydroxyacyl-CoA dehydrogenase,
multifunctional β-oxidation protein (3-ketoacyl-CoA thiolase), acyl-CoA synthase, malonyl -CoA
decarboxylase (MCD), CY P4A, and CPT-1. In addition, MCD, which controls the levels of malonyl-CoA,
is positively regulated by PPAR-α.[25]

The effect of alcohol on PPAR-α in alcoholic fatty liver has been investigated in cultured hepatocytes as
well as in ethanol-fed rodents. Alcohol has shown to inhibit PPAR-α activity both in vitro and in vivo
conditions.[26,27] Acetaldehyde, the metabolite of alcohol, is a key factor in the effect of alcohol on
PPAR-α. It is possible that acetaldehyde, because of its ability to covalently bind proteins, can form
adducts with the PPAR-α transcription complex, thereby preventing its ability to bind the promoter
element(s).[28,29]
Adiponectin in Alcohol Liver Disease In addition to PPAR-α, hepatic lipid metabolism has been shown to
be tightly regulated by adiponectin and adenosine monophosphate-activated protein kinase (AMPK).
Adiponectin is an adipose-derived hormone with a variety of beneficial biological functions.[30]
Increasing evidence suggests that altered adiponectin production in adipose tissue and impaired
expression of hepatic adiponectin receptors (AdipoRs) are associated with the development of alcoholic
liver steatosis in several rodent models.[31] It has been shown that the effect of adiponectin is largely
mediated by an increase in fatty acid oxidation, associated with activation of AMPK and PPAR-α
pathways and suppressing hepatic production of TNF-α.[32,33] It is well known that adiponectin and
TNF-α regulate the mutual production and antagonize their biological effects on the target tissues.
Although it is known that chronic ethanol consumption leads to increased circulating and local

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 3/9
3/28/13 Molecular mechanism of alcoholic fatty liver

concentrations of TNF-α,[34,35] it remains unclear whether increased TNF-α resulting from ethanol
feeding causes adiponectin reduction or whether suppression of adiponectin production by ethanol leads
to TNF-α induction.

Role of Adenosine Monophosphate-activated Protein Kinase AMPK is known to act as a key metabolic
“master switch” by phosphorylating the target enzymes involved in lipid metabolism in many tissues
including the liver. This enzyme, a heterotrimeric protein, is, itself activated by AMP as well as by
phosphorylation by liver kinase B-1.[36] When AMP activates the AMPK, it down-regulates energy
requiring pathways, generally lipid, RNA and protein synthesis. Conversely, AMPK activates ATP-
generating catabolic pathways, such as fatty acid oxidation, the TCA cycle and glycolysis.[37] It
phosphorylates and inhibits enzymes involved in lipid metabolism such as, 3-hydroxy-3-methyl
glutamate-CoA reductase and acetyl-CoA carboxylase (ACC).[38] In addition to the direct regulation of
the activity of the lipid metabolizing enzymes, AMPK also modulates SREBP-1 activity,[39] which plays
an important role in fatty acid synthesis.

Dephosphorylation of AMPK by protein phosphatase 2A (PP2A) causes AMPK inactivation. This PP2A
can be activated by ceramide, which is known to be increased after ethanol administration.[40–42]
Thus, ethanol increases the ceramide levels thus increasing PP2A activity, which in turn inhibits the
AMPK activity and increases the fatty acid synthesis.

Hepatic TGs: Export in VLDL and store in LDs The increased synthesis of free fatty acids in the liver of
alcoholics along with reduced ability of liver to oxidize these compounds can lead to increased synthesis
of TG, the main storage form of fat in liver. Fatty acids, stored as TG, are then imported into very low-
density lipoproteins (VLDL) particles, which are exported and transported in the serum to peripheral
tissues. The amount of fat, that can be exported in VLDL, will depend on synthesis of the protein
components, as well as the availability of TGs. Excess TGs are stored as lipid droplets (LDs) in the liver.
[43]

Ethanol Impairs Secretion of Very Low-density Lipoproteins from Liver Triacylglycerols are generally
exported from the liver by VLDL particles. These are assembled through a complex process and made up
of triglycerides, cholesterol, phosphatidylcholine, and apolipoproteins. These VLDLs are released into
circulation for delivery to the various tissues (primarily muscle and adipose tissue) for storage or
production of energy through oxidation. Inhibition of this process at any of several levels may result in
accumulation of triglycerides in hepatocytes and consequently development of fatty liver. Indeed, in
vivo studies[44,45] and in vitro studies,[46] VLDL secretion has been shown to be impaired after
ethanol administration. Alcohol may impair triglyceride export by inhibiting the synthesis of
phosphatidylcholine (via inactivating phosphatidylethanolamine methyl transferase activity), which is
an important component of VLDL formation.[47] Another proposed mechanism for reduced VLDL
secretion is inhibition of microtubular assembly by acetaldehyde produced during ethanol metabolism.
This is supported by studies in which inhibition of alcohol dehydogenase prevented the alcohol-induced
reduction of triacylglycerol.[47] In addition, alcohol may impair transport by inhibiting apolipoprotein
synthesis through inhibition of PPAR-α activity. Studies are required to understand the mechanisms
which impair the formation, intracellular transport through the cytoskeleton, and secretion of VLDL.

Impaired Lipid Droplet Metabolism Organisms store lipid when they take in more energy that can be
immediately used. This excess energy is packaged and stored for later use when the need for energy
outstrips available nutrient supply. In mammals, excess lipid intracellularly is stored in structures, most
commonly referred to as lipid droplets (LDs). LDs consist of a core of neutral lipids, surrounded by a
monolayer of phospholipids with attached or embedded proteins. The LDs proteome contains structural
proteins (e.g. proteins of the perilipin family), lipid-synthesis enzymes, lipases and membrane-
trafficking proteins.[48–50] Under normal or fasting conditions, healthy hepatocytes will metabolize
and degrade LDs by several mechanism that include the action of a series of associated lipases that

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 4/9
3/28/13 Molecular mechanism of alcoholic fatty liver

directly metabolize stored lipids. Members of the perilipin (PAT) family of LD-associated proteins,
including perilipin, adipophilin (ADRP) and TIP 47. These proteins regulate TG accumulation, either
through promotion of processes that enhance TG synthesis and packing in LDs or by controlling TG
lipolysis.[51–53] ADRP has been shown to be one of the major LD-associated proteins that can act to
attenuate lipolysis.[53] In animal studies, mice lacking ADRP have been shown to be protected against
fatty liver disease[54,55] and that ethanol feeding in rats is found to enhance ADRP expression in
association with hepatosteatosis.[56] In our studies, hepatic cells treated with alcohol have showed an
elevated LD accumulation and expression of the LD-associated protein, adipophilin.[46] Considered
together, these reports underline that the ethanol-amplified LD accumulation in hepatic cells involves
impairments in the LD metabolism as a consequence of altered LD associated proteins.

Conclusion
Alcoholic liver disease is associated with a state of hepatic fatty acid overload. In this review, we have
summarized the accepted pathways for alcohol-induced hepatic steatosis. In summary, ethanol
metabolism leads to excessive generation of reducing equivalents, thereby inhibiting fatty acid
oxidation. Recent studies indicate that additional effects of ethanol impair fat oxidation as well as
stimulate lipogenesis. The effects of ethanol on lipid metabolism result from inhibition of PPAR-α and
stimulation of SREBP-1, resulting in metabolic remodeling of the liver toward a fat-storing, rather than
fat oxidizing organ. These effects may, in turn, result from effects of ethanol on AMPK and adiponectin.
Inhibition of AMPK by ethanol feeding results in an increase in SREBP-1 activity. As a result, target
genes for SREBP-1 are up-regulated, contributing to an increased hepatic lipid synthesis and AMPK
inhibition also results in decreased fatty acid oxidation. AMPK may also affect the activity of PPAR-α.
Reduced PPAR-α activity will lead to reduced capacity for fatty acid oxidation. In addition to fatty acid
synthesis and oxidation, ethanol also alters the LDs (TG storage form) metabolism in hepatocytes and
inhibits the VLDL secretion from liver. All these reports help us to understand the intricacies of ethanol-
induced fatty liver.

Acknowledgments
The authors acknowledge the support provided by the Department of Veterans’ Affairs, and the NIH
(5RC1 AA019032).

Footnotes
Source of Support: Department of Veterans Affairs, and the NIH (5RC1 AA019032)

Conflict of Interest: None declared.

References
1. World Health Organization. The world health report -2002. Reducing risks, promoting healthy life.
2002. Available from: http://www.who.int/whr/2002/en/

2. Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab. 2008;295:E10–
6. [PMCID: PMC2493591] [PubMed: 18349117]

3. French SW. Ethanol and hepatocellular injury. Clin Lab Med. 1996;16:289–306. [PubMed: 8792073]

4. Zhou Z, Wang L, Song Z, Lambert JC, McClain CJ, Kang Y J. A critical involvement of oxidative
stress in acute alcohol-induced hepatic TNF-alpha production. Am J Pathol. 2003;163:1137–46.
[PMCID: PMC1868249] [PubMed: 12937155]

5. Crabb DW, Galli A, Fischer M, Y ou M. Molecular mechanisms of alcohol fatty liver: Role of
peroxisome proliferator-activated receptor a. Alcohol. 2004;34:35–8. [PubMed: 15670663]

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 5/9
3/28/13 Molecular mechanism of alcoholic fatty liver

6. Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic


steatohepatitis. Best Pract Res Clin Gastroenterol. 2011;25:231–44. [PubMed: 21497741]

7. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest.
2004;114:147–52. [PMCID: PMC449757] [PubMed: 15254578]

8. Y ip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol. 2006;23:149–60.
[PubMed: 17355088]

9. Fridman S. Stellate cell activation in alcoholic fibrosis-an overview. Alcohol Clin Exp Res.
1999;23:904–10. [PubMed: 10371412]

10. Gramenzi A, Caputo F, BisellI M, Kuria F, Loggi E, Andreone P, et al. Review article: Alcoholic liver
disease-pathophysiological aspects and risk factors. Aliment Pharmacol Ther. 2006;24:1151–61.
[PubMed: 17014574]

11. Savolainen VT, Liesto K, Mannikko A, Penttila A, Karhunen PJ. Alcohol consumption and alcoholic
liver disease: Evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res. 1993;17:1112–7.
[PubMed: 8279675]

12. Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad
Sci. 1975;252:85–105. [PubMed: 1096716]

13. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis.
1988;8:12–25. [PubMed: 3283941]

14. Day CP, James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114:842–5.
[PubMed: 9547102]

15. Lieber CS. New pathway of ethanol metabolism in the liver. Gastroenterology. 1970;59:930–7.
[PubMed: 4395020]

16. Lieber CS. Hepatic, metabolic and toxic effects of ethanol: 1991 update. Alcohol Clin Exp Res.
1991;15:573–92. [PubMed: 1928631]

17. Lieber CS, De Carli LM. Hepatotoxicity of ethanol. J Hepatol. 1991;12:394–401. [PubMed: 1845298]

18. Grunnet N, Kondrup J. The effect of ethanol on the beta-oxidation of fatty acids. Alcohol Clin Exp
Res. 1986;10:64S–8. [PubMed: 3544932]

19. Min Y , David WC. Recent advances in alcoholic liver disease II.Minireview: Molecular mechanisms
of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1–6. [PubMed: 15194557]

20. Brown MS, Goldstein JL. A proteolytic pathways that controls the cholesterol content of
membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999;96:11041–8. [PMCID: PMC34238]
[PubMed: 10500120]

21. Y ou M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid pathways by activation of
steroid regulatory element binding protein (SREBP) J Biol Chem. 2002;277:29342–7.
[PubMed: 12036955]

22. Reddy JK, Hashimoto T. Peroxisomal β-oxidation and peroxisome proliferator-activated receptor a:
An adaptive metabolic system. Annu Rev Nutr. 2001;21:193–230. [PubMed: 11375435]

23. Evans RM, Barish GD, Wang Y X. PPARs and the complex journey to obesity. Nat Med. 2004;10:1–
7.

24. Y u S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation,
steatohepatitis and hepatocarcinogenesis. Curr Mol Med. 2003;3:561–72. [PubMed: 14527087]

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 6/9
3/28/13 Molecular mechanism of alcoholic fatty liver

25. Lee GY , Kim NH, Zhao ZS, Cha BS, Kim Y S. Peroxisomal proliferator activated receptor- a activates
transcription of the rat hepatic malonyl-CoA decarboxylase gene: A key regulation of malonyl-CoA
level. Biochem J. 2004;378:983–90. [PMCID: PMC1224007] [PubMed: 14641110]

26. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with
reduced expression of peroxisome proliferator-a (PPAR-a)-regulated genes and is ameliorated by PPAR-
a activation. J Pharmacol Exp Ther. 2004;310:417–24. [PubMed: 15016835]

27. Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of
peroxisome proliferator activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism
for the development of ethanol-induced fatty liver. J Biol Chem. 2001;276:68–75. [PubMed: 11022051]

28. Tuma DJ, Hoffman T, Sorrell MF. The chemistry of acetaldehyde-protein adducts. Alcohol Alcohol
Suppl. 1991;1:271–6. [PubMed: 1845549]

29. Tuma DJ, Casey CA. Dangerous by products of alcohol breakdown-focus on adducts. Alcohol Res
Health. 2003;27:285–90. [PubMed: 15540799]

30. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: An adipokine regulating glucose and lipid
metabolism. Trends Endocrinol Metab. 2002;13:84–9. [PubMed: 11854024]

31. Xu A, Wang Y , Keshaw H, Xu LY , Lam KS, Cooper GJ. The fat-derived hormone adiponectin
alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100.
[PMCID: PMC162288] [PubMed: 12840063]

32. Y amauchi T, Kamon J, Minokoshi Y , Ito Y , Waki H, Uchida S, et al. Adiponectin stimulates glucose
utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–
95. [PubMed: 12368907]

33. Y amauchi T, Kamon J, Waki H, Imai Y , Shimozawa N, Hioki K, et al. Globular adiponectin
protected ob ⁄ ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem.
2003;278:2461–8. [PubMed: 12431986]

34. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor
in severe alcoholic hepatitis. Ann Intern Med. 1990;112:917–20. [PubMed: 2339855]

35. Jordi C, Ramo B, Pau S, Pablo B, Rosa M, Montserrat M, et al. Hepatic expression of candidate
genes in patients with alcoholic hepatitis: Correlation with disease severity. Gastroenterology.
2009;136:687–97.

36. Long Y C, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest.
2006;116:1776–83. [PMCID: PMC1483147] [PubMed: 16823475]

37. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: Possible roles in
type 2 diabetes. Am J Physiol. 1999;277:E1–10. [PubMed: 10409121]

38. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and
reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 2001;291:2613–6.
[PubMed: 11283375]

39. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, et al. Sustained peripheral
expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl
Acad Sci U S A. 2003;100:14217–22. [PMCID: PMC283572] [PubMed: 14617771]

40. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for
AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007;403:139–48.
[PMCID: PMC1828883] [PubMed: 17147517]

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 7/9
3/28/13 Molecular mechanism of alcoholic fatty liver

41. Liangpunsakul S, Wou SE, Zeng Y , Ross RA, Jayaram HN, Crabb DW. Effect of ethanol on
hydrogen peroxide-induced AMPK phosphorylation. Am J Physiol Gastrointest Liver Physiol.
2008;295:G1173–81. [PMCID: PMC2604799] [PubMed: 18832448]

42. Garcia-Ruiz C, Colell A, Mari M, Albert M, Maria C, Carlos E, et al. Defective TNF-α mediated
hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest.
2003;111:197–208. [PMCID: PMC151862] [PubMed: 12531875]

43. Michael WB. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: Possible role in
steatosis. Am J Physiol Gastrointest Liver Physiol. 2006;290:194–8.

44. Naoumova RP, Kim KD, Neuwirth C, Niththyananthan S, Rendell NB, Taylor GW, et al. Effect of
chronic ethanol feeding on the hepatic secretion of very-low-density lipoproteins. Biochim Biophys Acta.
1988;960:61–6. [PubMed: 3358946]

45. Kusum KK, Sandra LT, Brian WW, John JC, Dean JT. Betaine administration corrects ethanol-
induced defective VLDL secretion. Mol Cell Biochem. 2009;327:75–8. [PubMed: 19219625]

46. Benita LM, Karuna R, Dean JT, Mark AM, Carol AC. Lipid Droplet Accumulation and Impaired Fat
Efflux in Polarized Hepatic Cells: Consequences of Ethanol Metabolism. Int J Hepatol. 2012;2012:ID
978136. [PMCID: PMC3312290]

47. Wehr H, Rodo M, Lieber CS, Baraona E. Acetaldehyde adducts and autoantibodies against VLDL
and LDL in alcoholics. J Lipid Res. 1993;34:1237–44. [PubMed: 8371070]

48. Brown DA. Lipid droplets: Proteins floating on a pool of fat. Curr Biol. 2001;11:R446–9.
[PubMed: 11516669]

49. Bartz R, Zehmer JK, Zhu M, Chen Y , Serrero G, Zhao Y , et al. Dynamic activity of lipid droplets:
Protein phosphorylation and GTP-mediated protein translocation. J Proteome Res. 2007;6:3256–65.
[PubMed: 17608402]

50. Brasaemle DL. The perilipin family of structural lipid droplet proteins: Stabilization of lipid droplets
and control of lipolysis. J Lipid Res. 2007;48:2547–59. [PubMed: 17878492]

51. Robenek H, Hofnagel O, Buers I, Robenek MJ, Troyer D, Severs NJ. Adipophilin-enriched domains
in the ER membrane are sites of lipid droplet biogenesis. J Cell Sci. 2006;119:4215–24.
[PubMed: 16984971]

52. Wolins NE, Brasaemle DL, Bickel PE. A proposed model of fat packaging by exchangeable lipid
droplet proteins. FEBS Lett. 2006;580:5484–91. [PubMed: 16962104]

53. Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ, Brown DA. Adipocyte
differentiation-related protein reduces lipid droplet association of adipose triglyceride lipase and slows
triglycerol turnover. J Lipid Res. 2007;48:2751–61. [PubMed: 17872589]

54. Martinez-Botas J, Anderson JB, Tessier D, Lapillonne A, Chang BH, Quast MJ, et al. absence of
perilipin results in leanness and reverse obesity in Lepr(db/db) mice. Nat Genet. 2000;26:474–9.
[PubMed: 11101849]

55. Tansy JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, et al. Perilipin ablation results
in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-
induced obesity. Proc Natl Acad Sci U S A. 2001;98:6494–9. [PMCID: PMC33496] [PubMed: 11371650]

56. Mak KM, Ren C, Ponomarenko A, Cao Q, Lieber CS. Adipose differentiation-related protein is a
reliable lipid droplet marker in alcoholic fatty liver of rats. Alcohol Clin Exp Res. 2008;32:683–9.
[PubMed: 18341646]

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 8/9
3/28/13 Molecular mechanism of alcoholic fatty liver

Figures and Tables

Figure 1

Potential mechanisms underlying the alcoholic fatty liver. In liver, sterol regulatory element binding
protein 1 is responsible for fatty acid synthesis and peroxisome proliferator activated receptor-α,
AMPdependent protein kinase (AMPK) and adiponectin are responsible for fatty acid oxidation. Ethanol
may influence the activity of PPAR-α, SREBP-1, and AMPK directly or through adiponectin and tumor
necrosis factor-α. These effects activate the lipogenic pathways and inhibit fatty acid oxidation. Besides
the fatty acid synthesis and oxidation, ethanol also alters lipid droplets (LD, the storage form of TG)
metabolism in hepatocytes and very low-density lipoproteins secretion from liver. All these alterations
contribute to alcohol-induced fatty liver

Articles from Indian Journal of Pharmacology are provided here courtesy of Medknow Publications

www.ncbi.nlm.nih.gov/pmc/articles/PMC3371448/?report=printable 9/9